About: Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections
Creator	Hassan, Ferdaus Selvarangan, Rangaraj Lee, Brian Jackson, Mary
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Empiric antibiotic treatment is common among children with acute respiratory tract infections (ARTI), despite infections being predominately viral. The use of molecular respiratory panel assays has become increasingly common for medical care of patients with ARTIs. STUDY DESIGN: This was a 6-year retrospective, single-centered study of pediatric inpatients who tested positive for an ARTI respiratory pathogen. We examined the relationship between clinical outcomes and whether the patient was tested using the Luminex Respiratory Viral Panel ([RVP]; in-use: Dec. 2009 – Jul. 2012) or Biofire Respiratory Pathogen Panel ([RP]; in-use Aug. 2012 – Jun. 2016). The prevalence and duration of pre-test empiric antibiotics, post-test oseltamivir administration to influenza patients, chest x-rays and length of stay between the two assays was compared. RESULTS: A total of 5142 patients (1264 RVP; 3878 RP) were included. The median laboratory turn-around-time for RP was significantly shorter than RVP (1.4 vs. 27.1 h, respectively; p < .001). Patients tested with RP were less likely to receive empiric antibiotics (OR: 0.45; p < .001; 95% CI: 0.39, 0.52) and had a shorter duration of empiric broad-spectrum antibiotics (6.4 h vs. 32.9 h; p < .001) compared to RVP patients. RP influenza patients had increased oseltamivir use post- test compared to RVP influenza patients (OR: 13.56; p < .001; 95% CI: 7.29, 25.20). CONCLUSIONS: Rapid molecular testing positively impacts patient management of ARTIs. Adopting assays with a shorter turn-around-time improves decision making by decreasing empirical antibiotic use and duration, decreasing chest x-rays, increasing timely oseltamivir administration, and reducing length of stay.
has issue date	2018-11-23(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2018.11.006
bibo:pmid	30502640
has license	no-cc
sha1sum (hex)	8b5e58ca9be9b7f5ea6b429face62a42bde5d975
schema:url	https://doi.org/10.1016/j.jcv.2018.11.006
resource representing a document's title	Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections
has PubMed Central identifier	PMC7106386
has PubMed identifier	30502640
schema:publication	J Clin Virol
resource representing a document's body	covid:8b5e58ca9be9b7f5ea6b429face62a42bde5d975#body_text
is schema:about of	named entity 'MOLECULAR ASSAY' named entity 'CLINICAL MANAGEMENT' named entity 'ACUTE' named entity 'ANTIBIOTIC' named entity 'MULTIPLEX' named entity 'HOSPITALIZED CHILDREN' named entity 'TURN' named entity 'RESPIRATORY TRACT INFECTIONS' named entity 'IMPACT' named entity 'UTILIZATION' named entity 'TIME' named entity 'antibiotic' named entity 'respiratory tract infections' named entity 'diagnostic testing' named entity 'work-up' named entity 'diagnostic testing' named entity 'pathogens' named entity 'oseltamivir' named entity 'Idaho' named entity 'influenza' named entity 'jcv' named entity 'antibiotic' named entity 'antibiotic administration' named entity 'laboratory testing' named entity 'antibiotic' named entity 'hematology' named entity 'chest x-rays' named entity 'antibiotic' named entity 'molecular diagnostics' named entity 'pathogens' named entity 'bronchitis' named entity 'viruses' named entity 'bacterial pathogen' named entity 'radiation exposure' named entity 'medical/surgical' named entity 'antibiotic treatment' named entity 'influenza' named entity 'bacterial pathogen' named entity 'empiric treatment' named entity 'enterovirus' named entity 'empiric antibiotic' named entity 'empiric therapy' named entity 'NICU' named entity 'pathogens' named entity 'pathogen' named entity 'bacterial infections' named entity 'bronchiolitis' named entity 'pediatric patients' named entity 'hematology' named entity 'pathogens' named entity 'SAS' named entity 'pathogen' named entity 'empiric antibiotic' named entity 'anti-influenza' named entity 'bronchiolitis' named entity 'RSV' named entity 'acute otitis media' named entity 'MRPs' named entity 'oseltamivir' named entity 'rapid influenza test' named entity 'broad-spectrum' named entity 'common cold' named entity 'corticosteroids' named entity 'oncology' named entity 'human metapneumovirus' named entity 'Cary, NC' named entity 'signs and symptoms' named entity 'bronchiolitis' named entity 'NICU' named entity 'oseltamivir' named entity 'antibiotics' named entity 'radiographs' named entity 'sensitivity and specificity' named entity 'etiology' named entity 'bacteria' named entity 'viral infection' named entity 'SAS' named entity 'oseltamivir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software